American Diabetes Association
Browse

Systems biology and functional assessments of human iPSC-cardiomyocyte models of insulin resistance captures key hallmarks of diabetic cardiomyopathy

Download (9.17 MB)
figure
posted on 2025-09-16, 16:38 authored by Ryan D. Carter, Ujang Purnama, Marcos Castro-Guarda, Claudia N. Montes-Aparicio, Anandhakumar Chandran, Richard Mbasu, Maxwell Ruby, Charlotte Daly, Kirsti Brisk, Helen C. Christian, Jack J.J.J. Miller, Francesca M. Buffa, Lisa C. Heather, Carolyn A. Carr
<p dir="ltr">Human-centric models of diabetic cardiomyopathy (DbCM) are needed to provide mechanistic insights and translationally-relevant therapeutic targets for patients with diabetes. A systems biology approach using insulin resistant (IR) 2D human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and 3D engineered heart tissue (EHT) provides a comprehensive evaluation of dysregulated pathways and determines suitability as a translationally-relevant model of DbCM.</p><p dir="ltr">Culturing hiPSC-CMs in 2D or 3D EHT in “IR” media induced insulin resistance and activated multiple pathways implicated in DbCM, including metabolic remodelling, mitochondrial dysfunction, extracellular matrix remodelling, endoplasmic reticulum stress and blunted response to hypoxia, assessed using transcriptomics and proteomics. Metabolic flux measurements in both IR 2D and 3D platforms demonstrated increased fatty acid oxidation and lipid storage, whereas glucose metabolism was downregulated. Modelling DbCM in 3D EHTs conferred additional metabolic and functional advantages over the 2D hiPSC-CM, demonstrating impaired contractility and muscle architecture. Metformin treatment improved both contractility and metabolic function, demonstrating the utility of IR EHT for drug assessment.</p><p dir="ltr">In conclusion, IR 2D and 3D hiPSC-CM models effectively capture key DbCM features. However, 3D EHT provide additional insights into physiological and structural modifications. This highlights the potential of IR EHT for both mechanistic studies and drug screening in DbCM.</p>

Funding

This work was supported by a fellowship from the British Heart Foundation (FS/17/58/33072) and a studentship from the Biotechnology and Biological Science Research Council (BB/M011224/1). This work was funded by grants from the Rosetrees Trust (PGS19-2/10121), Novo Nordisk (NNOX_8) and the ERC (microC 772970).

History

Usage metrics

    Diabetes

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC